؉ T cells by Ag-loaded dendritic cells (DC) within secondary lymphoid tissue. However, the actual initiation of the response involves critical upstream events that control the recruitment of mature Ag-charged DC from the periphery via afferent lymphatics, events that are still only partly understood. Recent evidence has revealed that transmigration of lymphatic endothelium by DC is regulated by the adhesion molecules ICAM-1 and VCAM-1 both in vitro and in vivo. These findings imply that lymphatic entry may be an important rate-limiting step in primary immunity and a possible target for immune intervention. In this study, we have explored such possibilities using an F 5 TCR-transgenic mouse model to assess the contribution of lymphatic cell adhesion molecules in the CD8 ؉ T cell response to influenza virus nucleoprotein (NP). We show for the first time that immunization with ICAM-1-and VCAM-1-blocking mAbs can impair the T cell response in lymph node-draining sites of dermally administered nucleoprotein vaccine (MVA.HIVA.NP) by targeting lymphatic uptake of Ag-loaded DC ahead of other cell adhesion molecule-dependent events. These results reveal lymphatic entry as an important step that may be rate limiting in the development of immunity and reconfirm its potential as a target for localized immunotherapy in inflammation and tissue rejection.
T he efficient induction of a protective immune response to viral infection depends upon a series of encounters between naive T cells and relevant APC in the lymph nodes (1) . To facilitate such encounters, these organs maintain a unique architecture of cords and sinuses comprising endothelial and fibroblast reticular networks where naive Ag-specific T cells (typically 1 in 10 5 -10 6 of lymphoid cells) recruited from the circulation meet with cognate peptide-MHC complexes presented on dendritic cells (DCs) 5 entering via afferent lymph (2, 3) . Both the recruitment of naive lymphocytes in specialized lymph node high endothelial venules (HEV) and the stabilization of T cell-DC interactions in the cortex during Ag priming depend on intimate cell contacts facilitated by specific cell surface adhesion molecules including selectins, integrins, ICAM-1, and VCAM-1 (4). Although not complete, the molecular details of these events are relatively well understood.
Besides events in the lymph node itself, upstream steps such as entry of Ag-loaded DCs into afferent lymphatics are equally important, yet have received comparatively little attention. One major component of such trafficking is chemoattraction, thought to be induced by the lymph node/lymphatic endothelial-derived CC chemokines CCL21 and CCL19 via the shared receptor CCR7 expressed on mature DCs (5-9). However, the adhesion events targeted by these and other chemokines that promote leukocyte translymphatic migration are obscure.
We recently demonstrated in vitro induction of the leukocyte adhesion molecules ICAM-1, VCAM-1, and E-selectin in cultured lymphatic endothelial cells and provided evidence for their involvement in leukocyte adhesion/transmigration of the lymphatics in TNF-␣-mediated inflammation (10) . An important implication of these findings is that CAM-mediated entry of Ag-loaded DCs to afferent lymphatics may be a rate-limiting step during the development of primary T cell responses in draining lymph nodes. In this study, we have addressed the issue in a model of the CD8 ϩ T cell response to influenza virus A using the human nucleoprotein (NP) vaccine MVA.HIVA.NP (11) in F 5 TCR/C57BL/10 chimeric mice. We show for the first time that administration of neutralizing mAbs to either VCAM-1 or ICAM-1 can effectively block primary immunity by specifically targeting DC entry to afferent lymphatics. Moreover, at the dosages used in our experiments, the neutralizing mAbs showed no inhibitory effects on other key cell adhesion molecule (CAM)-dependent steps such as naive T cell recruitment or Ag priming in the lymph nodes. These results indicate that lymphatic adhesion/transmigration is an important step that may well be rate limiting during the generation of T cell responses and a previously unrecognized target for local immunotherapy in inflammation and immune-mediated disorders.
C57BL/10, C57BL/6, and F 5 mice were maintained at the Biomedical Services Unit (John Radcliffe Hospital, Oxford, U.K.) and studies were performed with appropriate Home Office licenses according to established institutional guidelines.
Adoptive transfer, anti-CAM blocking, and MVA.HIVA.NP injections

Naive CD8
ϩ T cells were isolated from F 5 -transgenic mice using the Dynal mouse CD8 ϩ negative isolation kit, stained with 5.5 M CFSE, resuspended in endotoxin-free PBS (7 ϫ 10 7 cells/ml), and administered i.v. into age-matched naive C57BL/10 mice (2 ϫ 10 6 cells/mouse). After 24 h, 0.5 mg of anti-ICAM-1, anti-VCAM-1 (see below), or control IgG Abs (Sigma-Aldrich) were administered i.p. into F5BL10 chimeras. After another 24 h, chimeras were immunized with 1 ϫ 10 7 PFU of recombinant modified vaccinia Ankara virus expressing flu-NP 366 -374 (MVA.HIVA.NP) either intradermally or i.v. CAM-blocking mAbs were administered again 24 h after MVA injection and mice were sacrificed a further 24 -72 h later (i.e., 2-4 days after MVA.HIVA.NP vaccination).
Sample preparation, cell surface staining, and FACS analysis
Draining lymph nodes (cervical) and/or spleens were harvested 4 days after MVA.HIVA.NP vaccination and stained for NP-specific CD8 ϩ T cells using human influenza virus A-NP 366 -374 -specific tetramer and anti-CD8 mAb. Single-cell suspensions were obtained, washed in FACS buffer (PBS, 1% FCS, and 0.01% sodium azide), incubated for 20 min at 37°C with flu-NP 366 -374 tetramer (1/160 dilution), costained with PECy7-conjugated anti-CD8␣ (1/150 dilution; BD Biosciences) for 15 min on ice, washed twice more with FACS buffer, and then resuspended in CellFix (BD Biosciences). Flu-NP 366 -374 tetramers were made as previously described (12) . Samples were acquired on a FACSCalibur with CellQuest software (BD Biosciences) and analyzed using FlowJo software (Tree Star).
Antibodies
The function blocking mAbs rat anti-mouse ICAM-1 (mAb YN1/1.7.4, (13)) and VCAM-1 (mAb 6C7.1 (14) ) were gifts from D. Vestweber (University of Mü nster, Mü nster, Germany). mAb to soluble mouse LYVE-1 Fc was generated in the rat (clone B1/10). Hamster anti-mouse podoplanin (clone 8.1.1) was purchased from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA). Rabbit anti-vaccinia virus (Lister strain) was from Acris. Alexa Fluor 568-conjugated goat anti-hamster and Alexa Fluor 488-conjugated goat antirabbit Ig were from Invitrogen and Cy5-conjugated goat anti-rat was from Chemicon International.
Whole-mount immunostaining
Tissues were prepared as described previously (10) and incubated with appropriate primary Abs overnight at 5 o C and fluorescent-conjugated secondary Abs for 2 h at 25 o C before mounting in Vectashield (Vector Laboratories). Samples were viewed on a confocal microscope (Radiance 2000; Bio-Rad) with sequential scanning.
In vivo migration of DC from dermis
To assess the contribution of nonspecific occlusion of transmigration by Ab-Ag complexes, contact hypersensitivity was induced in C57BL/6 male mice by topical application of 3% (w/v) oxazolone (4-ethoxymethylene-2 phenyl-2-oxazoline-5-one; Sigma-Aldrich) in 95% aqueous ethanol to both ears (50 l/ear) on 2 consecutive days. Four days after the sensitization phase, an i.p. injection of 0.5 mg of Ab in PBS was administered, either B1/10 (rat anti-mouse LYVE-1), YN1-1 (rat anti-mouse ICAM-1, as a positive control), or rat IgG. Twenty-four hours later, the mice were challenged by topical application of 0.8% oxazolone solution and 1.5 mg/ml FITC (Sigma-Aldrich) to the shaved abdomen, 150 l/animal. Mice were killed 24 h after challenge and axillary and inguinal lymph nodes were removed. Tissue was disrupted by 0.5 mg/ml collagenase D (Roche) for 30 min at 37 o C, passed through a 70-m cell strainer (BD Biosciences), and stained with PE-conjugated anti-mouse CD11c (BD Biosciences) for FACS analysis.
Lymphatic endothelial cell permeability assay
Primary human dermal lymphatic endothelial cells were seeded onto the underside of gelatin-coated Fluoroblok cell culture inserts (3-m pore size; BD Biosciences) and incubated for 2 h at 37 o C before being placed into a companion plate (BD Biosciences) containing EGM-2MV medium (Invitrogen). Cells were cultured until confluent and stimulated with 1 ng/ml TNF-␣ (R&D Systems) 24 h before use. Cells were incubated for 30 min at 37 o C in the presence of ICAM-1-blocking mAb 15.2 or mouse IgG before the addition of FITC-dextran, 100 g/ml, to the upper compartments of cell culture inserts. Fluorescence in the lower chambers was recorded at 30-min intervals at 37 o C, calibrated against a standard curve, and expressed as the concentration of dye in the lower chamber.
Results
Characteristics of the CD8 ϩ T cell response to human influenza NP in a TCR-transgenic mouse model
To generate a model of the primary CD8 ϩ T cell response to virus, we used F 5 TCR-transgenic mice in which 92-94% of the CD8 ϩ T cells carry a transgenic TCR recognizing the H-2D b immunodominant human influenza A/NT/60/68 virus NP epitope ASNEN-MDAM (15) . After fluorescent labeling with CFSE, the T cells were transferred to C57BL/10 mice that were then challenged with the cognate NP peptide epitope in the form of an intradermally administered modified vaccinia Ankara MVA-based vaccine MVA.HIVA.NP (11, 16) . As expected, ϳ90% of the NP-specific CD8 ϩ T cells sampled from the draining cervical lymph node showed proliferation in response to MVA.HIVA.NP (Fig. 1 , A and C). Moreover, activation was dependent upon MVA.HIVA.NP and virtually no T cell proliferation occurred in mice to which vaccine had not been administered (data not shown).
ICAM-1-and VCAM-1-blocking mAbs disrupt the MVA.HIVA.NP-specific CD8
ϩ T cell response ϩ T cells in the cervical lymph nodes detected by fluorescent NP-specific class I MHC tetramer staining (Fig. 1B) . Furthermore, both mAbs provoked a similar reduction in NP-specific CD8 ϩ T cell proliferation from a maximal level of 90% in animals injected with irrelevant IgG and MVA.HIVA.NP alone to 40% or less in CAM-blocked mice (Fig. 1C) . In contrast, there were no significant changes in T cell numbers in lymph nodes of mice that had received CAMblocking Abs but no MVA.HIVA.NP vaccine (typically 1% of the total CD8 ϩ T cells; Fig. 1D ). On this basis, we could exclude the obvious possibility that CAM-blocking Abs exerted their effects by inhibiting lymph node recruitment of naive T cells from the circulation through postcapillary HEV. This process is known to depend at least partly on ICAM-1 adhesion, but in these experiments, homing to lymphoid tissue had occurred before administration of CAM-blocking mAbs.
CAM-blocking mAbs do not affect T cell priming or activation
Since ICAM-1 is also known to be involved in stabilizing the immunological synapse that forms between naive T cells and APC (18, 19) during Ag priming in the lymph nodes (20) , we considered the additional possibility that the observed reduction in CD8 ϩ T cell proliferation might reflect synapse disruption or, alternatively, an upstream step such as initial Ag delivery in afferent lymphatics (see below). To address this question, we administered MVA. HIVA.NP vaccine i.v. rather than intradermally and analyzed the CD8 ϩ T cell response in spleen, an organ that lacks an afferent lymph supply and filters Ag directly from the blood for processing and presentation by resident splenic DC. In this way, we could quantify the contribution of CAMs to T cell priming independently of lymphatic trafficking. As shown in Fig. 2 , neither ICAM-1 nor VCAM-1 mAbs blocked splenic F 5 NP-specific T cell proliferation as assessed by CFSE fluorescence (Fig. 2, A and C) or NP-specific T cell numbers within the organ (Fig. 2B) . Furthermore, neither of the CAM mAbs affected recruitment of F 5 NP-specific T cells to spleen in non-MVA.HIVA.NP-vaccinated mice (Fig. 2D ). These results infer that the inhibitory effects of CAM blockade must be directed at some step other than T cell priming.
CAM-blocking mAbs impair entry of MVA.HIVA.NP-bearing APC into dermal lymphatics
Mature cutaneous DCs migrate to lymph nodes almost exclusively via afferent lymphatics, rather than through lymph node HEV (21) . Hence, the observed dependence on ICAM-1 and VCAM-1 might reflect either a role during entry to dermal lymphatic capillaries or migration toward the appropriate niche within the draining lymph node. To distinguish between these possibilities, we compared the uptake of injected MVA.HIVA.NP (detected with Alexa Fluorconjugated anti-vaccinia Abs) from the dermal injection site into skin lymphatics (detected with podoplanin Abs (22)) and its delivery to draining cervical lymph nodes in control and CAMblocked animals using whole-mount fluorescent immunostaining ( Fig. 3 and supplemental Fig. 1 ). Animals that received control Abs cleared the majority of MVA.HIVA.NP from the injection site within 48 h of vaccination, although trace levels of vaccine most likely representing free (non-APC-associated) material were still retained after this time period (Fig. 3A) , consistent with previous reports that residual vaccine can persist in the skin for several weeks (16) . In contrast, in those animals subjected to either ICAM-1 or VCAM-1 blockade, high levels of MVA.HIVA.NP were still visible near the vaccination site after 48 h (Fig. 3, B and  C) . Moreover, in the anti-CAM mAb-treated mice, most of the retained MVA.HIVA.NP could be seen accumulating around the perimeters of ICAM-1 and VCAM-1/podoplanin-dual positive lymphatic vessels, consistent with an interpretation that the block on CAM adhesion had impeded their engagement with endothelium and subsequent entry (Fig. 3, B and C) . Importantly, no such blocking effect was seen after administration of mAbs to another abundant lymphatic endothelial receptor LYVE-1 (Fig. 4A) , allowing possible bystander artifacts (i.e., nonspecific occlusion of transmigration by Ab-Ag complexes) to be excluded. In addition, in vitro studies with primary LEC in Boyden chambers showed that an ICAM-1-neutralizing Ab blocked only the transit of DCs across the endothelial monolayer (10) but had no effect on transit of large macromolecules (i.e., FITC-dextran), arguing against the possibility that the Abs had exerted their effects by inhibiting uptake of free vaccine into lymph (Fig. 4B) .
Next, we looked for an association between injected MVA. HIVA.NP and dermal APC during the time period (48 h) following HIVA.NP vaccine was injected into the ear flaps of mice that were also administered rat IgG (A), anti-VCAM-1 (B), or anti-ICAM-1 (C). Two days after vaccination, whole-mount staining was performed using an antivaccinia mAb with Alexa Fluor 488 (green), anti-podoplanin with Alexa Fluor 568 (red), and Cy5-conjugated goat anti-rat (blue) to detect binding of neutralizing mAbs. Bars, 100 m. vaccination. Using conditions of CAM Ab blockade to "freeze" uptake of APC into the afferent lymphatics, we found that a proportion of the injected MVA.HIVA.NP vaccine was indeed associated with class II MHC-positive cells in the dermis, most likely dermal DC or macrophages, while the remainder was more randomly distributed and appeared to represent retention of free or soluble vaccine (Fig. 5) . As expected, the anti-vaccinia Ab did not stain mouse dermis in the absence of MVA.HIVA.NP (supplemental Fig. 2 ). To determine whether this latter component also entered the afferent lymphatics and trafficked to the lymph node independently of APC, we looked for the arrival of skin-injected MVA.HIVA.NP in draining cervical lymph nodes of control and CAM mAb-treated mice 48 h after vaccination. As shown by the whole-mount fluorescence images in Fig. 6A , vaccine was detectable in the nodes of control mice. However, this was invariably associated with the cellular milieu of the paracortical region, the site where Ag-charged APC arriving in afferent lymph might be expected to congregate. in close proximity to proliferating (CFSE low ) NP-specific F 5 T cells. In contrast, no vaccine (either free or cell associated) was detected in nodes from animals treated with ICAM-1-or VCAM-1-blocking mAbs (Fig. 6, B and C) , a finding that was further confirmed by the markedly diminished level of NP-specific T cell proliferation (i.e., the preponderance of CFSEhigh T cells). Altogether, these data argue that the vaccine detected in cervical node paracortex must have derived from immigrant tissue APC and that vaccine-loaded APC rather than soluble vaccine provide the major contribution to the flu-NP T cell response in this model. Moreover, we conclude from these studies that CAM-mediated efflux of APC across afferent lymphatic capillaries, while not the sole mechanism for such efflux, constitutes a key step that may be rate limiting to development of a primary CD8 ϩ T cell response and a potential target for specific Ab intervention.
Discussion
It is well documented that the adhesion molecules ICAM-1 and VCAM-1 play key roles in the immune response. These range from the adhesion of lymphocytes to APCs for immune priming to the firm adherence of effector T and B cells and neutrophils to vascular endothelium that enables their extravasation and engagement with target Ag in the tissues. Indeed, the abundant expression of ICAM-1 and VCAM-1 in activated vascular endothelium coupled with the numerous observations that blocking Abs could inhibit lymphocyte adhesion in vitro has led to the notion that such Abs should be effective in suppressing immune and inflammatory responses in vivo. Consistent with this notion, ICAM-1 knockout mice were found to have a diminished capacity for delayed-type skin hypersensitivity responses, mixed lymphocyte responses, and the elicitation of peritoneal neutrophil immigration (23) . Moreover, administration of ICAM-blocking Abs in mice and nonhuman primates was shown to have dramatic effects in either preventing or ameliorating renal, cardiac, and hepatic allograft rejection (24 -26) , ischemia-reperfusion injury (27) , colitis (28), autoimmune collagen-induced arthritis (12) , and contact hypersensitivity (29, 30) . In the majority of these instances, the Abs were assumed to target late events in the immune response, namely, the extravasation of effector cells from the blood circulation or their interaction with target cells in the tissues (31, 32) . The possibility that effective targets for ICAM-1 or VCAM-1 blockade might be present during earlier steps in the process, such as lymphatic entry, has received far less attention.
Unlike the blood vasculature, it is only recently that endothelial adhesion molecules have been implicated in immune cell trafficking in afferent lymphatics (10, 33) . The prevailing dogma long held that such trafficking must be indolent, due to the fact that initial lymphatics have loose interendothelial junctions that have been assumed not to present a physical barrier to cell entry (reviewed in Ref. 34 ). However, it has recently been shown that both ICAM-1 and VCAM-1 are induced in lymphatic endothelial cells exposed to inflammatory cytokines in vitro and in vivo and that they can mediate leukocyte adhesion/transmigration in inflammation (10, 35) . The issue now is whether such CAMs in afferent lymphatics actually regulate initiation of an immune response and whether this step represents a new target for immunosuppression.
In this study, we have presented evidence that adhesion/transmigration of Ag-charged DCs to afferent lymphatics is indeed rate limiting during the development of an immune response, using as a model the F 5 CD8
ϩ T cell response to a defined influenza NP peptide epitope in C57BL/10 chimeric mice. We have shown that administration of ICAM-1-and VCAM-1-blocking Abs before and after intradermal immunization with the flu-NP vaccine MVA.
HIVA.NP inhibits CD8
ϩ T cell expansion in skin-draining lymph nodes. This is evidenced by the dramatic reduction (60%) in proliferation of CFSE-labeled NP tetramer-positive T cells therein, the failure in clearance of MVA.HIVA.NP-loaded DCs from the injection site, their diminished recruitment in the nodes, and their increased accumulation at the perimeter of dermal lymphatics. The apparently equal potency of ICAM-1-and VCAM-1-blocking mAbs in these experiments mirrors results we obtained previously using an in vitro transmigration assay where the individual effects were also shown to be nonadditive (8) , further supporting the notion that the two adhesion receptors support sequential steps in lymphatic adhesion/transmigration. This contrasts with the mechanism used by monocytes during transmigration of blood capillary endothelium in which VCAM-1 and ICAM-1 have been shown to support separate alternative pathways (36) .
The remaining component (40%) of NP-specific CD8 ϩ T cell proliferation that is not inhibited by CAM Ab blockade may reflect incomplete saturation of lymphatic endothelial CAMs at the Ig levels used in our studies or more likely the involvement of components other than ICAM-1/VCAM-1 in the transmigration process, as concluded in our earlier studies into lymphatic trafficking of DCs in skin-delayed type hypersensitivity responses. Although it is also possible that this Ab-insensitive component of T cell proliferation represents a response to soluble vaccine delivered directly in afferent lymph, this seems unlikely from our data, as no such vaccine could be detected in draining nodes of animals treated with ICAM-1-or VCAM-1-neutralizing Abs. Some material corresponding to "free" MVA.HIVA.NP was found to be retained in skin close to the injection site 48 h after vaccination. However, we conclude that most if not all of this component is eventually scavenged by phagocytes or further waves of APC rather than being taken up directly into afferent lymph.
The lack of any obvious effect of CAM blockade on other relevant processes mediated by ICAM-1 or VCAM-1 such as naive T cell recruitment through lymph node HEV or T cell priming through TCR-MHC engagement during lymphocyte DC interactions in the lymph nodes is interesting. Although CAM mAbs would be expected to block such processes if administered at sufficiently high doses, those used in our studies appeared to preferentially target the lymphatics, consistent with the primacy of lymphatic entry as a regulatory step during initiation of the immune response.
Based on these considerations, we conclude that CAM-mediated lymphatic adhesion/transmigration should be considered as a potential target for immunosuppression. Unlike previous applications of CAM Ab therapy which have targeted late events such as the CAM-dependent extravasation of effector T cells during active tissue rejection or CAM-dependent allorecognition of transplanted tissue by allospecific T cells, the targeting of lymphatics would inhibit a very early event, the initial recruitment of APC to the lymph nodes. Although the lymphatics are likely to have been unwitting targets of CAM Ab blockade in previous studies, their specific targeting, for example by local rather than systemic Ab administration or by appropriate Ab conjugation could further improve effectiveness. The mouse anti-human ICAM-1 mAb Enlimomab showed promise in early trials for inflammatory conditions such as ischemic stroke, renal allograft rejection (37) , and rheumatoid arthritis (38) . However, this was seriously compromised by autoimmune responses to the Ab itself and resulting immune complex-associated side effects (39 -41) . In light of our present findings, the trial of humanized ICAM-1 or VCAM-1 Abs (for example, Ref. 42) in formats that specifically target the lymphatics is worthy of renewed consideration.
